Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 May 22;213(3):235–244. doi: 10.1159/000531098

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 S. Karger AG, Basel

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.

PMC Copyright notice

Fig. 4. — Macrophage primary cilium lengthening inhibits osteoclastogenesis. mRNA quantification of genes involved in osteoclast differentiation or function showed that fenoldopam treatment prior to osteoclast differentiation treatment resulted in an 18.2% decrease in expression of tartrate-resistant acid phosphatase (Acp5) (a), a 20.3% decrease in expression of cathepsin K (Ctsk) (b), no change in dendritic cell-specific transmembrane protein (Dcstamp) (c), a 28.5% decrease in c-Fos (d), and no change in nuclear factor of activated T cells, cytoplasmic 1 (Nfatc1) (e), when compared to the DMSO vehicle control (n = 4). f Samples treated with fenoldopam also formed osteoclasts at a lesser rate, indicated by a 13% drop in osteoclast surface area coverage (n = 24, 23).